



K A N S A S

JANET SCHALANSKY, SECRETARY

KATHLEEN SEBELIUS, GOVERNOR

SOCIAL AND REHABILITATION SERVICES

Health Care Policy / Medical Policy Division
Scott Brunner, Director

**State of Kansas Medicaid Program
Preferred Drug List Advisory Committee Meeting**

October 07, 2004, 10:00am – 4:00pm

Capitol Plaza Hotel

Pioneer Room, Maner Conference Center

1717 S.W. Topeka Boulevard

Topeka, Kansas

Open Session Agenda

- I. Call to Order
- II. Introductions
- III. Review and Approval of June 16, 2004, Meeting Minutes
- IV. Urinary Incontinence (UI) Drugs
 - A. Public Comment
 - B. Committee Discussion
 - C. Committee Recommendation/Action
- V. Beta Blockers (BB)
 - A. Public Comment
 - B. Committee Discussion
 - C. Committee Recommendation/Action
- VI. Oral Hypoglycemics (OH)
 - A. Thiazolidinediones
 - 1. Public Comment
 - 2. Committee Discussion
 - 3. Committee Recommendation/Action

- B. Sulfonylureas
 - Glipizide (Glucotrol®, Glucotrol XL®, and generics)
 - Glipizide/Metformin (Metaglip®)
 - Glyburide (Diabeta®, Micronase®, Glynase PresTab®, and generics)
 - Glyburide/Metformin (Glucovance®)
 - Glimepiride (Amaryl®)
 - 1. Public Comment
 - 2. Committee Discussion
 - 3. Committee Recommendation/Action
- C. Meglitinides
 - 1. Public Comment
 - 2. Committee Discussion
 - 3. Committee Recommendation/Action
- D. Biguanides
 - 1. Public Comment
 - 2. Committee Discussion
 - 3. Committee Recommendation/Action
- E. Alpha-Glucosidase Inhibitors
 - 1. Public Comment
 - 2. Committee Discussion
 - 3. Committee Recommendation/Action
- VII. ARBs
 - A. Public Comment
 - B. Committee Discussion
 - C. Committee Recommendation/Action
- VIII. Adjournment

**12:00pm to 12:45pm – Lunch for Committee Members